Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce

4.8/5 on G2· Since 2015

Aardvark Therapeutics Appoints David Zhang as Class II Director

PUBLIC · AARDOct 08, 2026

New to company · from Abivax S.A.“He previously served as Chief Strategy Officer at Abivax S.A.”

Position

Director

Company

Aardvark Therapeutics

David Zhongwei Zhang, Ph.D., MBA

San DiegoManufacturingBiotechnology

Description

On October 6, 2026, Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II director of the company, effective October 7, 2026. Dr. Zhang brings over 25 years of experience in clinical program design and regulatory submissions

Company Information

Company

Aardvark Therapeutics

Location

12707 HIGH BLUFF DRIVE

San Diego, California, United States

About

Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications. Aardvark's lead compound, oral ARD-101, is a potent bitter taste receptor (TAS2R) pan-agonist that stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones including GLP-1 and the satiety hormone Cholecystokinin (CCK), which activates gut-brain neurologic signaling to mediate hunger. ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies. Based on promising clinical data from an ongoing ARD-101 trial, the FDA has granted the drug both Orphan Drug designation and Rare Pediatric Rare Disease designation in PWS.

Fundz sees it the moment Aardvark Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Book a demo Explore plans